Ohr Pharmaceutical Inc., of New York, reported that additional interim data from the phase II IMPACT study evaluating squalamine eye drops (OHR-102) in wet age-related macular degeneration (AMD) showed improved best-corrected visual acuity (BCVA) in patients who received the combination of OHR-102 and Lucentis (ranibizumab,